Replies to post #76376 on Biotech Values

[DewDiligence]

IDIX ReadMeFirst

[Updates:
2009 news flow;
EASL PR’s and poster presentations for IDIX’s three HCV programs;
new version of “HCV: Most Likely to Succeed” post based on data
reported at EASL (the most consequential change for IDIX investors
is the apparent demise of ANA598 from ANDS).]


What is IDIX’s business all about?
#msg-35391933 IDX899 deal makes IDIX a ‘pure play’ HCV company
#msg-35945929 Addressable markets for antiviral drugs
#msg-36966276 IDIX’s drug portfolio
HCV synopsis from IDIX website


Valuation and finances
#msg-35671327 4Q08 financial results
#msg-35706808 Musings on IDIX’s liquidity
#msg-35740500 Status of Tyzeka
#msg-35740500 Fair market value of Tyzeka royalty stream
#msg-29157548 Standstill agreement with NVS has expired
#msg-36280241 Table of recent biotech buyouts


News flow
#msg-37320081 2009 clinical goals


Officers, directors, and major shareholders
#msg-35471801 Composition of Board of Directors
Capsule résumés of executive officers (click on a name)
#msg-33807169 Largest shareholders
#msg-29157548 Standstill agreement with NVS has expired
#msg-33807081 Latest NVS “true up” purchase
#msg-33625817 NVS’ cost basis
#msg-35737993 Current insider shareholdings
#msg-32238060 Recent insider transactions


HCV program: Economic rationale and competition
#msg-37321586 HCV: Most Likely to Succeed (IMHO)
HCV drugs on market and in development
#msg-29018192 Prevalence and incidence of HCV in the US
#msg-30190435 Devastating risk of undertreating HCV
#msg-34694166 US prevalence of genotypes 1a and 1b
#msg-34797714 Annual sales of ifn-alpha drugs
#msg-36780163 Musings on HCV combination therapy
#msg-36474682 Musings on the future role of interferon (1)
#msg-34925415 Musings on the future role of interferon (2)
#msg-34927675 Musings on the different classes of HCV drugs


HCV program: IDX184 nucleotide polymerase inhibitor
#msg-36392616 Abstract for 2009 EASL conference
#msg-36696042 Nucleoside vs Nucleotide
#msg-26915921 Why IDX184 is better than NM283
#msg-34763865 Phase-1/2 monotherapy study
#msg-28715477 Preclinical data


HCV program: IDX375 non-nucleoside polymerase inhibitor
#msg-37263272 Apparent demise of ANA598 is bullish for IDIX375
#msg-37270158 More on the same topic (ANA598)
#msg-37246670 EASL 2009 press release
#msg-37315636 EASL 2009 poster presentation
#msg-31043481 2008 PR announcing the IDX375 program
#msg-34334563 Blurb on IDX375 from hivandhepatitis.com


HCV program: IDX136/316 protease inhibitors
#msg-35628221 Rationale for IDX136/316 and distinction between them
#msg-37246670 EASL 2009 press release
#msg-37315636 EASL 2009 poster presentation
#msg-31043481 2008 PR announcing the PI program
#msg-36600884 Musings on selectivity of HCV PI’s


HIV program
#msg-35391933 IDIX inks worldwide partnership with GSK
#msg-37211836 The New Battle Lines in HIV
#msg-37210457 Market data from GILD’s 1Q09 CC
#msg-35674369 HIV market overview (2007 article from CNNMoney)
#msg-35740500 Musings on Truvada’s patent status
HIV drugs on market and in development
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-35109525 Sustiva (which IDX899 might supersede) sells $1.2B/yr
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment (1)
#msg-36745396 New guidelines to recommend earlier treatment (2)
#msg-37210627 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial


Reference links
http://www.idenix.com/hepc/about
http://www.hcvdrugs.com/
http://www.hivandhepatitis.com
http://www.aidsmeds.com/list.shtml